Answers are grounded in this paper and cite their sources.
One of the most critical differences in the posttransplant care of children and adults is the essential requirement in children to maintain a state of health that supports normal physical and psychological development. These 2 aspects of health have been studied both separately and jointly because the outcomes may be interrelated and share common risk factors. Several aspects of physical growth and cognitive development have been reported in children receiving liver transplantation, primarily in single-center, retrospective series. The effect of chronic liver disease, frequently complicated by malnutrition, on growth potential and neurodevelopmental processes is poorly understood. Furthermore, the effect of chronic posttransplant immunosuppressive exposure, particularly that of calcineurin inhibitors, on central nervous system development is not known. Growth failure is a common problem in children awaiting liver transplantation.1, 2 Anthropometric measurements, including height and weight, can be compared across age ranges by the use of z scores, standardized scores that indicate by how many standard deviations an observation is above or below the age-specific and gender-specific mean. Several studies have suggested that the mean z score for height in this population at the time of liver transplantation is in the −1.0 to −1.75 range.1-5 Data regarding weight in the pretransplant period can be difficult to interpret because, similar to adults, many children with chronic liver disease and portal hypertension will have increased extracellular fluid volumes secondary to ascites and peripheral edema. Thus, linear growth failure is a more reliable indicator of malnutrition and advancing liver synthetic failure. Linear growth failure in children with cirrhosis has been the focus of several investigations and appears to be mediated by growth hormone resistance.6 Circulating levels of insulin-like growth factor I (IGF-I), which is synthesized in the liver, and insulin-like growth factor binding protein 3 are low in children with chronic liver disease, despite elevated growth hormone levels.7 Furthermore, treatment with exogenous growth hormone does not increase IGF-I levels or improve growth. Following successful liver transplantation, growth hormone and IGF-I levels return to normal, and the rate of linear growth improves.8 However, it appears that many children do not achieve their height potential even years after transplantation. Chronic malnutrition also contributes to growth failure in children awaiting liver transplantation. It has been observed, however, that even with adequate caloric intake, many children with cirrhosis and advanced liver disease cannot achieve normal growth. Several factors make it difficult to improve nutritional status in this patient group. Fat malabsorption, abnormal nitrogen metabolism, and increased energy expenditure are well-established features of end-stage liver disease in children, and malnutrition and growth failure are considered to be important risk factors for poor outcomes following liver transplantation.9, 10 Focused management of nutrient intake in the pretransplant period may improve some patients as candidates for liver transplantation and reduce their risk of posttransplant growth failure. However, children with growth failure that is a result of progressive liver disease will not improve as transplant candidates even with meticulous nutritional care. These patients will, in fact, continue to deteriorate, and expedient transplantation is the only option to improve growth.11 When a trial of intensified nutritional support is not successful in restoring somatic fat and muscle stores within 4 to 6 weeks, it should be assumed that the patient's liver synthetic function is no longer adequate to support growth. Reviews of nutritional support for children with liver disease before and after liver transplantation have recently been published.12, 13 Nutritional status can be assessed by measurement of the upper extremity triceps skin fold thickness and mid-arm muscle circumference, which can be performed in even small infants of less than 5 kg. Depletion of fat reserves, as measured by triceps skin fold, is an early indicator, and diminished somatic muscle, as measured by mid-arm muscle circumference, is an advanced sign of protein-calorie malnutrition. Caloric needs are increased in children with end-stage liver disease because of malabsorption and increased resting energy expenditure. Anorexia, also a common problem in infants with advanced liver disease, worsens as organomegaly and ascites distend the abdominal cavity. Delivery of adequate caloric intake to these children can be challenging. Recommended caloric intake for children with chronic liver disease is 130%-150% of the recommended daily intake based on ideal body weight. In infants, the usual range is 120-150 kcal/kg/day. Formula preparations that contain the majority of fat as medium chain triglycerides (MCT) are recommended for infants with biliary atresia and other causes of cholestasis or biliary obstruction. However, a balance must be struck between providing MCT supplementation to enhance fat absorption and maintaining the palatability of the formula. A well-tolerated approach is to add MCT oil to standard infant formula or breast milk to increase the caloric density. Nasogastric feeding may be required as a supplement when oral intake is diminished. A continuous nocturnal nasogastric feeding schedule is preferred to allow infants to maintain oral feeding skills. Fat-soluble vitamin supplementation is essential in children with chronic cholestasis. Table 1 includes recommended dosages for these individual vitamins. Many pediatricians will begin prophylaxis with an over-the-counter preparation that contains water-soluble vitamins and high levels of the fat-soluble vitamins A, D, E, and K in a water-miscible form. This approach is successful in some, and frequent monitoring of vitamin levels will identify patients who require more aggressive supplementation with individual doses. Clinical manifestations of vitamin deficiency are most commonly observed for vitamins D and K. Coagulopathy in patients receiving oral vitamin K may still be corrected with administration of parenteral vitamin K. Likewise, patients that develop osteopenia and clinical rickets while on oral ergocalciferol (vitamin D2) may respond to more aggressive supplementation with calcium and 25-OH vitamin D. Following transplantation, liver function and nutritional status return to normal, and the rate of growth accelerates. This phenomenon is described as “catch-up growth.” Catch-up growth for weight occurs more rapidly than for height, and mean weight z scores for this population approach normal by the end of the first posttransplant year.14 However, in many series, catch-up linear growth is not observed until the second postoperative year.1, 2, 4, 15 It also appears that the height distribution of children after liver transplantation is consistently lower than that of normal children, and this suggests that catch-up growth is not complete4, 14 (see Fig. 1). Linear growth following liver transplant is negatively correlated with the need for retransplantation and steroid usage.1, 4, 16 The impact of the height z score at transplant on linear growth following transplant may vary with age. Infants less than 2 years old with more severe height deficits may display excellent catch-up growth.4 Yet, older children with well-established short stature prior to transplant may not. Original diagnosis and age-dependent posttransplant complications, such as diabetes, may be important confounding variables. Growth over time for patients with at least 12 months of follow-up.14 Figure previously published in: Group SR. Studies of pediatric liver transplantation (SPLIT) year 2000 outcomes. Transplantation 2001;72:463-476. A recent multivariate analysis of growth impairment in 432 children in the Studies of Pediatric Liver Transplantation registry studied at 24 months post-transplant revealed that height and weight at transplant, steroid exposure, primary liver disease, posttransplant diabetes, single-parent household, and transplant prior to 2001 all independently predicted linear growth impairment. Patients with higher z scores for height and weight at transplant and those with biliary atresia were less likely and those that received steroids beyond 18 months post-transplant were more likely to be growth-impaired (z score < −1.28). Glucocorticoid exposure is a well-known cause of linear growth failure and delayed bone age. However, the degree of growth retardation is not always predicted by current or cumulative doses of glucocorticoid. Serum concentrations of methylprednisolone vary in individual children receiving similar doses and are better correlated with growth velocity than dose.8, 17 However, clinical practice has not incorporated this measurement of glucocorticoid exposure. Instead, physicians have relied on the observation of cushingoid features and growth delay to indicate increased sensitivity to methylprednisolone doses. Most treatment protocols in children include minimization or elimination of steroid exposure for stable patients between 6 and 18 months following transplantation. This practice likely contributes to the observation that linear height velocity is more accelerated in this time period. In some cases, ongoing steroid therapy is indicated for the treatment of late graft rejection or autoimmune complications. In this setting, exogenous growth hormone therapy may be a reasonable treatment for linear growth impairment. Several trials of recombinant human growth hormone (rhGH) administration following liver transplantation have been conducted. In short-term studies, linear growth velocity did improve in treated patients.18, 19 A recently published long-term trial reported that the treatment response was sustained in the second and third treatment years without the bone age advancing beyond chronological age. This observation suggests that prolonged rhGH therapy would not have a negative impact on the duration of linear growth and adult height potential.20 Concerns have been raised in both renal and liver transplant recipients that rhGH may contribute to the development of late allograft rejection. These small trials in pediatric liver transplant recipients have not validated those concerns. Pretransplant liver disease and chronic glucocorticoid exposure following liver transplantation would also be expected to impair bone mineralization in this population. Yet, several studies have suggested that bone mineral density returns to normal after transplantation.21-24 One of these, which included a long-term follow-up evaluation of 15 adults who received liver transplants as children, revealed standard deviation scores for bone density that were within the normal range (total body, −0.92 ± 1.2, and lumbar spine, −0.42 ± 1.2).24 In this group, bone density was not impacted by gender, pretransplant cholestasis, or age at transplant. HRQOL, health-related quality of life; IGF-I, insulin-like growth factor I; IM, intramuscular; IQ, intelligence quotient; MCT, medium chain triglycerides; RDA, recommended daily intake; rhGH, recombinant human growth hormone; TPGS, d-alpha-tocopheryl poly (ethylene glycol) 1000 succinate. Developmental outcomes can be measured in several ways, and measurement is dependent on the age at testing. Measures of infant development focus on motor function, social and environmental interaction, and language development. Older children can be tested for intelligence, academic achievement, behavior, and adaptation skills. Abnormalities that are observed later in childhood are more predictive of static deficits that will persist into adulthood. Malnutrition and growth failure before liver transplant are important risk factors for delayed cognitive development.25-29 Investigators at the University of Texas conducted some of the first studies evaluating cognitive function in children before and after transplantation. Stewart et al.25 tested a heterogeneous group of 36 children who were 4 years old or older when they were referred for liver transplant. Children who developed liver disease in infancy had significantly lower intelligence quotient (IQ) scores than children who became symptomatic later in life (mean ± standard deviation for full-scale IQ = 85 ± 8.8 versus 99.5 ± 13.8). A subsequent study of 43 school-age children with advanced liver disease confirmed that onset of symptoms of liver disease in the first year of life, independent of diagnosis, had a strong negative impact on cognitive function.30 These investigators also studied children longitudinally before and after transplantation. Again, children with persistent developmental delay after transplant were more likely to have had onset of disease in the first year of life.27 Developmental delay, a frequent problem in infants awaiting liver transplantation, does not reverse quickly after transplant.29 Infant development has been studied prospectively in patients with biliary atresia and end-stage liver disease who received liver transplantation before 2 years of age. While they were awaiting transplant, mental and motor developmental scores were within the low average range. At 3 months following transplant, standardized scores dropped even further and recovered only to pretransplant levels at 12 months after the procedure. Thus, it appears that development slows or stalls during the immediate postoperative period and that patients do not exhibit developmental “catch-up” until after the first posttransplant year. Infants with longer hospitalizations and those with growth impairment at transplant had more significant delays. Developmental delay secondary to chronic liver disease in infancy and acute or chronic hepatic encephalopathy in older children may result in enduring cognitive deficits and learning disabilities even after successful liver transplantation.31 Intelligence cannot be accurately assessed until children have well-developed language skills, usually after 4 to 5 years of age. IQ is a standardized measurement of intelligence that can be used to predict educational achievement and special needs. The IQ score is standardized to a population mean of 100, with most tests having a standard deviation of 15 points. One common criterion for diagnosis of mental retardation is a tested IQ of 70 or below in a patient with associated deficits in adaptive functioning. Intelligence has been evaluated in several cross-sectional studies of older children at various intervals following liver transplantation.31-34 Findings have revealed that the mean IQ values are within the low average range, but in some series, the transplant group mean IQ scores were significantly lower than the population mean.31, 32 Some of this impact may be secondary to an increased number of patients with lower IQ scores. A significant discrepancy between standardized intelligence scores and academic achievement is one of the accepted definitions of learning disability. Children with learning disabilities can benefit from special educational support and can qualify for mandated individualized educational plans. Learning disabilities have been observed in up to 26% of pediatric liver transplant recipients.31 The specific causes of these disabilities have not yet been systematically studied. One study observed significant language deficits in children following liver transplantation that were independent of hearing loss.34 Children with language delay following liver transplantation must be carefully screened for hearing deficit because this is a prevalent problem, with severe hearing loss observed in 5% of children in long-term follow-up.35 Data collected through the Studies of Pediatric Liver Transplantation registry revealed that learning disability had been diagnosed in 17.7% of liver transplant recipients versus 8% of the general population. Forty-two percent of the posttransplant population had a history of receiving special educational services (unpublished data). Psychosocial adaptation of liver transplant recipients, as measured by the Child Behavior Checklist, compared favorably to that of normal children.36-38 However, a more in-depth assessment of this same group of children suggested that liver transplant recipients had more anxiety and depressive symptoms than normal children.38 A recent study that included patient and parent structured interviews revealed evidence of behavioral or emotional disturbances in 50% of 18 patients.39 These findings again suggest that, similar to intellectual and academic function, psychosocial function may appear normal on superficial examination. Specific deficits are only recognized when targeted for focused evaluation. We cannot extrapolate data regarding health-related quality of life (HRQOL) from adult transplant recipients to children because the primary disease, process of care, and surgical and infectious complications differ among the 2 populations. Furthermore, this process is complicated by the need to account for changes in expected role functioning as the child matures. Thus, children of different ages require measurements with different instruments. Children also have a longer life span following liver transplantation, and functional status in childhood may have an important impact on outcomes in adulthood. Initial studies reporting HRQOL in children following liver transplantation asserted that, for the most part, quality of life for pediatric transplant recipients was “good.”3, 40, 41 However, these studies were cross-sectional, did not use validated instruments, and did not address all of the domains that constitute HRQOL. Consequently, the meaning of “good” quality of life was unclear. A recent review of the literature discusses 11 studies in which quality of life for liver transplant recipients was measured distinctly from growth or survival.42 When the studies were examined as a group, there was a trend toward poorer HRQOL in liver transplant recipients compared to healthy populations. Overall, the results were comparable among the studies. Two of these single-center studies were conducted in parallel at the University of Cincinnati and Northwestern University and used the same parent-report HRQOL instrument.43, 44 The results were strikingly similar. Parents of these patients reported that the physical function of their children was lower than that of healthy children but was similar to that of children with chronic illness. Psychosocial function, especially school function, was also reported to be lower. The University of Cincinnati study found that higher HRQOL was associated with increasing time since liver transplant, white race, fewer hospitalizations, older age at transplant, and higher maternal education.44 A recent report that included assessment of HRQOL obtained directly from adolescent liver transplant recipients found that these patients reported physical and psychosocial function very similar to that of a healthy middle school population.45 However, their parents reported physical function that was significantly lower. All of these studies also identified parental emotional distress and disruption of family activities as more common problems in this population. Until this past year, all studies evaluating HRQOL in this population were from single centers, and all but one was cross-sectional. In the one longitudinal study, the investigators found that HRQOL improved with time since transplantation in 38 children under the age of 5 years.46 Scores for all physical and psychosocial domains, except global mental health, increased from before transplantation to 6 months after transplantation. A recently reported multicenter study evaluated HRQOL at 2 years following liver transplantation in 102 children, 67 of whom were younger than 5 years of age.47 Findings in the older children were similar to previously published reports with lower physical health and increased parental and family stress. The younger children, 2 to 5 years old, scored lower than controls in overall assessment of global health and general health perceptions but did not differ in subscales measuring physical and psychosocial function. Univariate analysis among the subscales identified demographic but not clinical variables as significant of HRQOL in these younger Thus, it appears that children who have liver transplantation, especially those older than 5 physical function that is lower than that reported for normal children but may approach that of patients with other chronic and that demographic factors and from transplant may have a significant impact on functional outcomes. Children who are younger at the time of transplant may have better functional outcomes. of psychosocial function have on the used and the child versus but they do suggest diminished school function. Parents of these patients report more emotional distress than of healthy children and a potential negative impact on other family Children who have received liver transplants to report their physical function to be higher than their normal growth and development in children that have end-stage liver disease and liver transplantation is a growth failure prior to transplant may have a negative impact on posttransplant growth and cognitive development. Yet, with the current most infants and children with chronic liver disease will advanced malnutrition and growth failure before they have an to a liver physical and developmental “catch-up” is observed for many children, some do not pretransplant to posttransplant such as steroid may improve outcomes. The cognitive function of the majority of patients is within the normal range. Yet, a high are not functioning at the that would be predicted by their IQ, and the specific causes of learning problems in this group must be more HRQOL and functional outcomes are comparable to those of other pediatric with chronic disease but are lower than those of a population. Parents of pediatric liver transplant recipients report more and to report functional outcomes that are lower than those reported by the children
No takes yet. Share an insight, caveat, or question.
Estella M. Alonso (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: